CMPS · COMPASS Pathways plc

COMPASS Pathways reported a transformative first quarter 2026, swinging to a net income of $91.2 million from a net loss of $17.9 million in the same period last year. The swing was primarily driven by a $130.9 million non-cash gain from the fair value adjustment of warrant liabilities, reflecting the significant increase in the company's share price. Operating expenses decreased to $42.9 million from $49.6 million, with R&D expenses declining to $26.5 million as the Phase 3 program for COMP360 in treatment-resistant depression (TRD) nears completion, and G&A expenses falling to $16.4 million due to lower legal and professional fees. The company ended the quarter with a robust cash position of $466.0 million, bolstered by successful financing and warrant exercises, providing cash runway well into 2028. Management highlighted regulatory acceleration, including FDA grant of rolling NDA submission and review, and the award of a Commissioner's National Priority Review Voucher (CNPV) for COMP360, which could compress review time to 1-2 months. The final NDA submission remains on track for Q4 2026, with the company aiming to be launch-ready by year-end. CEO Kabir Nath emphasized the transformative clinical profile of COMP360, which has shown rapid and durable effects in over 1,000 participants across three late-stage trials. The company also expects 26-week Part B data from the COMP006 trial in early Q3 2026. Overall, the quarter marks a pivotal shift from clinical-stage to pre-commercial stage, with strong financial footing and accelerated regulatory momentum.